BPMC - Blueprint Medicines' Ayvakyt gets approval in EU to treat systemic mastocytosis

The European Commission approved the expanded use of Blueprint Medicines' (NASDAQ:BPMC) Ayvakyt (avapritinib) as a monotherapy for adult patients with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm or mast cell leukemia, after at least one systemic therapy. Systemic mastocytosis is a rare disorder that results in too many mast cells, a type of white blood cell, building up in the body. The approval follows positive opinion from a committee of the European Medicines Agency in January. In Europe, the company plans to begin its first commercial launch in Germany. The drug is already approved in the EU to treat certain patients with gastrointestinal stromal tumors.

For further details see:

Blueprint Medicines' Ayvakyt gets approval in EU to treat systemic mastocytosis